Get the Stockscreener App
35.77
1.30%
-0.47
After Hours:
35.77
Royalty Pharma Plc stock is traded at $35.77, with a volume of 4.24M.
It is down -1.30% in the last 24 hours and down -1.51% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$36.24
Open:
$36.435
24h Volume:
4.24M
Relative Volume:
1.06
Market Cap:
$15.46B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
15.55
EPS:
2.3
Net Cash Flow:
$827.02M
1W Performance:
+0.36%
1M Performance:
-1.51%
6M Performance:
+5.99%
1Y Performance:
+29.09%
1-Day Range:
$35.42
$36.44
1-Week Range:
$35.31
$36.70
52-Week Range:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.77 | 15.67B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Wedge Capital Management L L P NC Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma at Bernstein Forum: Strategic Insights on Growth By Investing.com - Investing.com UK
Transcript : Royalty Pharma plc Presents at Bernstein Insights - MarketScreener
Mn Services Vermogensbeheer B.V. Acquires Shares of 67,000 Royalty Pharma PLC $RPRX - MarketBeat
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? - MSN
Royalty Pharma PLC $RPRX Shares Sold by Ridgewood Investments LLC - MarketBeat
Strs Ohio Invests $1.89 Million in Royalty Pharma PLC $RPRX - MarketBeat
Pacific Capital Partners Ltd Sells 77,500 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Sell Signal: Does HAIN align with a passive investing strategyPortfolio Gains Report & Fast Momentum Entry Tips - khodrobank.com
Analyst Downgrade: Why is Royalty Pharma plc stock going downJuly 2025 Trends & AI Enhanced Trading Alerts - khodrobank.com
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today - Sahm
Understanding Royalty Pharma plc’s price movementJuly 2025 Trends & Short-Term Swing Trade Alerts - newser.com
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum - The Manila Times
Leading Biopharma Royalty Investor Royalty Pharma Featured at Bernstein Healthcare Forum 2025 - Stock Titan
Layoff Watch: Will Royalty Pharma plc benefit from rate cutsWeekly Trend Recap & Stock Market Timing Techniques - khodrobank.com
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 226,048 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Market Outlook: Should I buy Royalty Pharma plc stock now2025 Market Overview & Daily Entry Point Alerts - خودرو بانک
Royalty Pharma (NASDAQ:RPRX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Nasdaq Moves: What are the analyst revisions for GCLWWIs Royalty Pharma plc stock a good investment in YEARJuly 2025 Macro Moves & Verified Chart Pattern Trade Signals - خودرو بانک
Royalty Pharma’s $2 Billion Debt Offering Could Be a Game Changer for RPRX - simplywall.st
TD Cowen Maintains a Buy on Royalty Pharma (RPRX) - Insider Monkey
Royalty Pharma Plc Experiences Evaluation Revision Amidst Market Dynamics and Performance Variability - Markets Mojo
Syndax, Royalty Pharma enter into $350M royalty funding deal - MSN
12 Affordable Biotech Stocks to Invest In Now - Insider Monkey
Empowered Funds LLC Buys New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Completes $2 Billion Senior Notes Offering - TipRanks
Royalty pharma to buy its external manager, announces $3B share buyback - MSN
Royalty Pharma stock price target raised to $38 from $37 at UBS - Investing.com Nigeria
Gainers Report: Will Royalty Pharma plc outperform the market in YEARMarket Sentiment Summary & Stock Timing and Entry Methods - خودرو بانک
Street Watch: Does Santech Holdings Limited Depositary Receipt offer margin of safetyGlobal Markets & Fast Gain Swing Trade Alerts - khodrobank.com
Royalty Pharma (RPRX) PT Raised to $38 at UBS, But Firm on Sidelines Due to Structural Issues - StreetInsider
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts - Yahoo Finance
Royalty Pharma Plc's (NASDAQ:RPRX) Prospects Need A Boost To Lift Shares - 富途牛牛
Aug Chart Watch: Is Royalty Pharma plc stock technically oversoldTrade Risk Assessment & Community Verified Trade Alerts - خودرو بانک
Petrus Trust Company LTA Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Signal Recap: Will Royalty Pharma plc be affected by tariffs2025 Earnings Surprises & AI Powered Market Entry Strategies - خودرو بانک
USS Investment Management Ltd Sells 42,500 Shares of Royalty Pharma PLC $RPRX - MarketBeat
EP Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Evaluating Valuation After $2 Billion Debt Offering and New Capital Moves - Sahm
Uniplan Investment Counsel Inc. Purchases 11,904 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Stake Lessened by Baird Financial Group Inc. - MarketBeat
TD Cowen reiterates Buy rating on Royalty Pharma stock, citing strong metrics - Investing.com Nigeria
Royalty Pharma: Investor Day Upside (NASDAQ:RPRX) - Seeking Alpha
TD Cowen Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Alliancebernstein L.P. Purchases 86,873 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):